JP2000516807A5 - - Google Patents

Download PDF

Info

Publication number
JP2000516807A5
JP2000516807A5 JP1998508087A JP50808798A JP2000516807A5 JP 2000516807 A5 JP2000516807 A5 JP 2000516807A5 JP 1998508087 A JP1998508087 A JP 1998508087A JP 50808798 A JP50808798 A JP 50808798A JP 2000516807 A5 JP2000516807 A5 JP 2000516807A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998508087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000516807A (ja
JP3977434B2 (ja
Filing date
Publication date
Priority claimed from US08/740,223 external-priority patent/US6265564B1/en
Application filed filed Critical
Publication of JP2000516807A publication Critical patent/JP2000516807A/ja
Publication of JP2000516807A5 publication Critical patent/JP2000516807A5/ja
Application granted granted Critical
Publication of JP3977434B2 publication Critical patent/JP3977434B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50808798A 1996-08-02 1997-08-01 改変tie―2レセプターリガンド Expired - Lifetime JP3977434B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2299996P 1996-08-02 1996-08-02
US60/022,999 1996-08-02
US08/740,223 US6265564B1 (en) 1996-08-02 1996-10-25 Expressed ligand-vascular intercellular signalling molecule
US08/740,223 1996-10-25
PCT/US1997/013557 WO1998005779A1 (en) 1996-08-02 1997-08-01 Modified tie-2-receptor ligands

Publications (3)

Publication Number Publication Date
JP2000516807A JP2000516807A (ja) 2000-12-19
JP2000516807A5 true JP2000516807A5 (enExample) 2005-04-07
JP3977434B2 JP3977434B2 (ja) 2007-09-19

Family

ID=26696604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50808798A Expired - Lifetime JP3977434B2 (ja) 1996-08-02 1997-08-01 改変tie―2レセプターリガンド

Country Status (20)

Country Link
US (5) US6265564B1 (enExample)
EP (1) EP0915974B1 (enExample)
JP (1) JP3977434B2 (enExample)
KR (1) KR100481560B1 (enExample)
CN (1) CN1171997C (enExample)
AT (1) ATE262037T1 (enExample)
AU (1) AU724032C (enExample)
CA (1) CA2262409C (enExample)
CZ (1) CZ295371B6 (enExample)
DE (1) DE69728149T2 (enExample)
DK (1) DK0915974T3 (enExample)
ES (1) ES2216163T3 (enExample)
HU (1) HU227995B1 (enExample)
IL (1) IL128311A (enExample)
NO (1) NO990470L (enExample)
NZ (2) NZ333994A (enExample)
PL (1) PL189639B1 (enExample)
PT (1) PT915974E (enExample)
RU (1) RU2233880C2 (enExample)
WO (1) WO1998005779A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1141294B1 (en) * 1998-12-23 2005-03-02 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of ligands
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
CA2397833A1 (en) * 2000-01-20 2001-07-26 Hadasit Medical Research Services & Development Company Ltd. Novel haptotactic peptides
EP1303483B1 (en) 2000-08-21 2008-04-23 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7052695B2 (en) 2001-10-25 2006-05-30 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of treating hypertension
WO2003048185A2 (en) * 2001-11-30 2003-06-12 Genvec, Inc. Angiopioetin related factors
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
WO2004076650A2 (en) * 2003-02-27 2004-09-10 The Trustees Of The University Of Pennsylvania Angiopoietin and fragments, mutants, and analogs thereof and uses of the same
WO2005013890A2 (en) * 2003-05-29 2005-02-17 The Trustees Of The University Of Pennsylvania Function and regulation of angiopoietin-3/angiopoietin-4
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
AU2004266242A1 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
CN1323723C (zh) * 2003-12-26 2007-07-04 上海新世界基因技术开发有限公司 Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
AU2010237130B2 (en) * 2009-04-13 2015-01-29 Apceth Gmbh & Co. Kg Engineered mesenchymal stem cells and method of using same to treat tumors
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
KR101967345B1 (ko) * 2012-10-18 2019-04-09 삼성전자주식회사 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
RU2538701C1 (ru) * 2013-07-11 2015-01-10 Федеральное государственное бюджетное учреждение науки "Тюменский научный центр Сибирского отделения РАН" (ТюмНЦ СО РАН) Способ извлечения куриного эмбриона из яйца для дальнейшего получения клеточных трансплантатов из фетальных тканей
EP3198023B1 (en) 2014-09-26 2020-04-22 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
WO2017079556A1 (en) 2015-11-06 2017-05-11 Regeneron Pharmaceuticals, Inc. Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070192A (en) * 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
CA2216963C (en) * 1995-04-06 2010-06-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000500076A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000506853A5 (enExample)
JP2000502568A5 (enExample)
JP2001502270A5 (enExample)
JP2000514669A5 (enExample)
JP2000501774A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2002515743A5 (enExample)
JP2000516807A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2001503914A5 (enExample)
JP2000500318A5 (enExample)
JP2000500184A5 (enExample)
JP2000512996A5 (enExample)
JP2000502479A5 (enExample)